Please login to the form below

Not currently logged in

Pfizer's Wyeth acquisition gets EC go ahead

Pfizer has announced that the EC has cleared its $68bn purchase of Wyeth

Pfizer has announced that the European Commission(EC) (under the European Union Merger Regulation authorisation process) has cleared its $68bn purchase of Wyeth.

"We are pleased to have achieved another significant milestone for the pending acquisition with the EC's approval of the transaction," said Amy Schulman, senior vice president and general counsel of Pfizer.

Pfizer agreed to buy Wyeth in January, but approvals from regulators and governments on several continents are required due to the size of the businesses involved. Pfizer has also said that the Chinese Ministry of Commerce has extended its review of the deal beyond the initial 30 days. Meanwhile, in the US, a 90-day regulatory review continues.

Wyeth shareholders are scheduled to vote on the merger today and the deal is expected to close at the end of the third quarter or during the fourth.

20th July 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...